Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2980 | Optifast VLCD Program Wiki | 0.71 |
drug2990 | Oral load of oxalate and sucralose Wiki | 0.71 |
drug1887 | High Oxalate Diet Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D007669 | Kidney Calculi NIH | 0.82 |
D053040 | Nephrolithiasis NIH | 0.50 |
D015431 | Weight Loss NIH | 0.24 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000787 | Nephrolithiasis HPO | 0.50 |
HP:0001824 | Weight loss HPO | 0.24 |
Navigate: Correlations HPO
There are 2 clinical trials
This study consists of having subjects, those with calcium oxalate kidney stones as well as healthy controls, consume low and oxalate enriched diets to investigate the role of oxalate on crystalluria (the presence of crystals in urine), immunity and infection.
Description: Twenty-four hour urinary oxalate will be reported as mg/day
Measure: Urinary Oxalate Time: Change between Baseline and Diets at 4 daysDescription: Twenty-four hour crystalluria will be reported as particles/ml
Measure: Crystalluria Time: Change between Baseline and Diets at 4 daysDescription: Cellular bioenergetics will be reported as oxygen consumption rate
Measure: Monocyte Cellular Bioenergetics Time: Change between Baseline and Diets at 4 daysDescription: Monocyte mitochondrial complex activity will be reported as oxygen consumption rate
Measure: Monocyte Mitochondrial Complex Activity Time: Change between Baseline and Diets at 4 daysDescription: Monocyte transcriptomics will be reported as gene expression (mRNA levels)
Measure: Monocyte Transcriptomics Time: Change between Baseline and Diets at 4 daysThis protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in obese calcium oxalate stone formers.
Description: Subjects will ingest a controlled diet low in oxalate and collect 2 x 24-hour urines before and after the Optifast VLCD Program. The utilization of a low oxalate diet allows assessment of the change in contribution of endogenous oxalate synthesis to the urinary oxalate pool.
Measure: Measurement of 24 hour urinary oxalate excretion Time: Day 4Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports